Dacogen Approval History
FDA Approved: Yes (First approved May 2, 2006)
Brand name: Dacogen
Generic name: decitabine
Dosage form: for Injection
Company: MGI Pharma Inc. and SuperGen Inc.
Treatment for: Myelodysplastic Diseases
Dacogen (decitabine) is a hypomethylating agent indicated for treatment of patients with myelodysplastic syndromes (MDS), a cancer of the bone marrow.
Development History and FDA Approval Process for Dacogen
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.